Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study

Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study

Abstract Introduction This analysis aims to describe real-world clinical outcomes in US African American and Hispanic patients with systemic lupus erythematosus (SLE) receiving belimumab. Methods In this post hoc analysis of OBSErve US (GSK Study 117,295) data, patients received intravenous belimuma...

Full description

Bibliographic Details
Main Authors:	Christopher F. Bell, Jake Chung, Bernard Rubin
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-01-01
Series:	Rheumatology and Therapy
Subjects:	African American ethnicity Belimumab Hispanic ethnicity Real-world data Systemic lupus erythematosus
Online Access:	https://doi.org/10.1007/s40744-022-00524-y

Similar Items

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022-11-01)

Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report
by: Marco Scarati, et al.
Published: (2017-04-01)

Belimumab in systemic lupus erythematosus
by: Ankita Srivastava
Published: (2016-01-01)

Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
by: E. L. Nasonov, et al.
Published: (2021-09-01)

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
by: O. Capdevila, et al.
Published: (2023-07-01)

RESULTS OF AN OBSERVATIONAL PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF BELIMUMAB (BENLYSTA®) IN SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL CLINICAL PRACTICE
by: E. A. Aseeva, et al.
Published: (2016-03-01)

EXPERIENCE WITH BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. A. Aseeva, et al.
Published: (2015-09-01)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
by: Marlene Plüß, et al.
Published: (2020-05-01)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
by: Guzman M, et al.
Published: (2020-06-01)

Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
by: Han Zhang, et al.
Published: (2023-12-01)

Real-World Effectiveness of Belimumab in Patients with Active Lupus
by: Yuya Sumichika, et al.
Published: (2023-12-01)

Belimumab in childhood systemic lupus erythematosus: A review of available data
by: Feng Chen, et al.
Published: (2022-07-01)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
by: Cevey M, et al.
Published: (2019-12-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

Short‐term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus
by: Chunye Wu, et al.
Published: (2022-11-01)

Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review
by: Chisato Yoshijima, BSPharm, et al.
Published: (2024-01-01)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
by: Francesca Regola, et al.
Published: (2019-04-01)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
by: Sabih Ul Hassan, et al.
Published: (2020-08-01)

PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. L. Nasonov, et al.
Published: (2014-06-01)

Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
by: Tania Colasanti, et al.
Published: (2022-01-01)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
by: Kyriakos A. Kirou, et al.
Published: (2022-08-01)

The perception of the African-American community through the eyes of the Hispanic media in the U.S.: a critical discourse analysis of the reporting of the death of Michael Brown
by: Stephenie De Cort, et al.
Published: (2016-05-01)

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
by: Jing Wang, et al.
Published: (2023-02-01)

Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial
by: Mieke van Schaik, et al.
Published: (2022-11-01)

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus
by: Hao Cheng, et al.
Published: (2022-08-01)

Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
by: Patrick Muller, et al.
Published: (2020-07-01)

Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report
by: Francesco Fontana, et al.
Published: (2018-10-01)

Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study
by: Dahai Wang, et al.
Published: (2022-12-01)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
by: Ioannis Parodis, et al.
Published: (2022-04-01)

An update on the management of refractory cutaneous lupus erythematosus
by: Alice Verdelli, et al.
Published: (2022-09-01)

THE EFFICIENCY OF BIOLOGICAL THERAPY AND THE FEATURES OF HUMORAL IMMUNITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: A. A. Mesnyankina, et al.
Published: (2018-07-01)

Balamuthia Amebic Encephalitis Risk, Hispanic-Americans
by: Frederick L. Schuster, et al.
Published: (2004-08-01)

Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab
by: Luca Quartuccio, et al.
Published: (2023-01-01)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
by: Gomez A, et al.
Published: (2023-01-01)

Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender
by: Shuilian Yu, et al.
Published: (2023-06-01)

THE TIME COURSE OF CHANGES IN B LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING THERAPY WITH BIOLOGICAL AGENTS
by: A. A. Mesnyankina, et al.
Published: (2017-07-01)

Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review
by: Domenico Paolo Emanuele Margiotta, et al.
Published: (2018-03-01)

Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus
by: Panagiotis Athanassiou, et al.
Published: (2023-07-01)

Enrollment of underrepresented racial and ethnic groups in the Rare and Atypical Diabetes Network (RADIANT)
by: Mustafa Tosur, et al.
Published: (2023-01-01)

Lupus nephritis - case report of an uncommon succession of therapies
by: Andreea Rovinaru, et al.
Published: (2023-12-01)